A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study.

ABSTRACT:

SUBMITTER: Spagnuolo V 

PROVIDER: S-EPMC6352870 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature